iBio selects IBIO-201 as its leading COVID-19 vaccine candidate

iBio Inc.

iBio (NYSE AMERICAN:IBIO) selected IBIO-201 as its leading candidate for the prevention of SARS-CoV-2 infection.

iBio previously reported that both of its COVID-19 vaccine candidates, IBIO-200 and IBIO-201, in combination with select adjuvants, induced the production of anti-SARS-CoV-2 antibodies. 

The company noted new data demonstrating that IBIO-201, its lichenase booster molecule subunit vaccine, induced the production of more anti-spike neutralizing antibodies than IBIO-200 in immunized mice.

“Our decision to evaluate IBIO-200 and IBIO-201 in tandem, and in combination with multiple adjuvants, proved beneficial given the results observed with IBIO-201 in preclinical studies,” Tom Isett, iBio’s chairman and CEO, said in a statement.

He added that while IBIO-201 produced significantly higher anti-spike neutralizing antibody titers than IBIO-200, the company is still encouraged by the potential of IBIO-200.

“We plan to conduct more focused studies on each of IBIO-200 and IBIO-201, with the goal of advancing IBIO-201 to toxicology studies ahead of planned clinical development.  Meanwhile, we intend to continue preclinical development of IBIO-200 and our virus-like particle platform as a potential ‘plug-and-play’ vaccine development system,” Mr. Isett said.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.